ASX Near Peak Territory While Biotech, BNPL and SaaS Tumble on Risk-Off Shift

Aditi Sarkar

02 March 2026 08:49 PM AEDT

ASX Near Peak Territory While Biotech, BNPL and SaaS Tumble on Risk-Off Shift

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

The ASX 200 finished near its record high, but losses were concentrated in high-growth and rate-sensitive sectors
Mesoblast led the laggards, dropping 7.58% as biotech volatility and regulatory uncertainty weighed on sentiment
Zip Co tumbled 8.37% amid concerns over funding costs, margins and weaker consumer spending trends
Travel-linked SiteMinder and Web Travel declined as demand normalisation and macro uncertainty pressured valuations.

The S&P/ASX 200 edged up 2.30 points on Monday to 9,200.90 as investors rotated into gold and energy plays following geopolitical tensions that pushed commodity prices higher. The index remains just 0.02% below its 52-week high after a 1.94% five-day gain, but market breadth stayed weak with most sectors in the red. The rally in oil-linked stocks masked sharp declines across high-beta growth, travel, fintech and biotech names, which dominated the list of the day’s biggest losers.

Mesoblast Limited (ASX:MSB) Declines 7.58% – Biotech Volatility Returns

Mesoblast fell 7.58% to AUD 2.07, losing AUD 0.17, emerging as one of the top losers on the ASX.

Reason for Decline

The decline may be attributed to:
• Profit booking following prior speculative rally
• Investor caution around clinical trial timelines
• Regulatory uncertainty
• Broader risk-off sentiment in high-beta biotech stocks

Financial Overview

Mesoblast operates as a regenerative medicine biotechnology company focused on cellular therapies. Revenue remains milestone-based, profitability depends on approvals, operating expenses are R&D-heavy, and cash flow is typically negative, requiring capital raises. Balance sheet strength is tied to cash reserves and funding access.

Technical Levels & Outlook

Support: $1.90
Resistance: $2.30

If $1.90 fails, further downside toward $1.75 is possible. Recovery above $2.30 may stabilize sentiment.

The stock is trading below its 20-day and 50-day moving averages, indicating short-term weakness. Price has slipped beneath the rising trendline resistance near AUD 2.40, increasing downside risk. RSI is hovering around 31.88, approaching oversold territory, suggesting selling pressure remains elevated. Immediate support is seen near AUD 1.90. A sustained move back above AUD 2.60 would be needed to stabilise momentum and revive bullish sentiment.

Analyst View

Seen as a high-risk, high-reward biotech where long-term value depends on clinical and commercialization success.

Risks

Clinical trial failure
• Regulatory rejection
• Capital dilution risk

Zip Co Limited (ASX:ZIP) Drops 8.37% – BNPL Weakness Resurfaces

Zip declined 8.8.37% to AUD 1.75, losing AUD 0.15.

Reason for Decline

Weak consumer spending data
• Rising funding costs
• Margin compression concerns
• Regulatory scrutiny in BNPL sector

Financial Overview

Revenue comes from merchant fees and instalment products. Profitability depends on credit performance and funding costs. Cost reductions and geographic rationalisation have improved the balance sheet, but leverage and funding access remain key.

Technical Levels

Support: AUD 1.60
Resistance: AUD 2.00
Break below support could extend the correction.

ZIP is trading below key horizontal trendline support and remains under its 20-day and 50-day moving averages, signalling short-term weakness. The break beneath the rising trendline near AUD 2.64 has heightened downside risk. RSI at 35.18 is nearing oversold levels, reflecting persistent selling pressure. Immediate support lies around AUD 1.50, while a move above AUD 2.30 is needed to restore bullish momentum.

Analyst View

Cautiously optimistic post-restructuring, but macro headwinds persist.

Light & Wonder Inc. (ASX: LNW) Falls 6.97% – Gaming Pullback

Light & Wonder dropped 6.97% to AUD 124.85, losing AUD 9.36.

Reason for Decline

Profit booking after strong rally
• Slower gaming revenue growth concerns
• Broader tech sector weakness

Financial Overview

Diversified across gaming machines and digital platforms, with improving EBITDA margins and strong cash flow, but sensitive to discretionary spending.

Technical Levels

Support: $115
Resistance: $135

LNW is trading below a key rising trendline support and remains under its 20-day and 50-day moving averages, indicating sustained short-term weakness. The breakdown below AUD 138.40 has intensified downside pressure. With RSI at 26.60, the stock is in oversold territory, suggesting heavy selling momentum. Immediate support is seen near AUD 110.00, while a recovery above AUD 140.50 would be required to stabilise sentiment and revive bullish momentum.

Analyst View

Strong fundamentals intact, though near-term valuation correction risk remains.

SiteMinder Limited (ASX:SDR) Slips 7.77% – SaaS Growth Sensitivity

SiteMinder declined 7.778% to AUD 3.320, losing AUD 0.270.

Reason for Decline

Travel demand normalisation
• SaaS growth slowdown concerns
• High valuation sensitivity

Financial Overview

Subscription-based revenue provides visibility, margins are improving with scale, but profitability is sensitive to acquisition costs and travel trends.

Technical Levels

Support: $3.00
Resistance: $3.60

SDR is trading below a key horizontal trendline support and remains under its 20-day and 50-day moving averages, indicating sustained short-term weakness. The breakdown below AUD 4.16 has intensified downside pressure. With RSI at 33.92, the stock is in oversold territory, suggesting heavy selling momentum. Immediate support is seen near AUD 2.90, while a recovery above AUD 4.16 would be required to stabilise sentiment and revive bullish momentum.

Analyst View

Long-term SaaS growth story remains, with near-term volatility.

Web Travel Group Limited (ASX:WEB) Falls 6.50% – Travel Cooling

Web Travel dropped 6.50% to AUD 3.02, losing AUD 0.205.

Reason for Decline

Travel demand cooling
• Profit booking
• Global macro uncertainty

Financial Overview

Revenue is driven by online bookings and B2B distribution. Margins improve with volume, while earnings remain sensitive to travel demand and currency movements.

Technical Levels

Support: AUD 2.85
Resistance: AUD 3.30

WEB continues to exhibit pronounced technical weakness, trading decisively below key horizontal support and its 20-day and 50-day moving averages. The breakdown under AUD 3.87 has reinforced a bearish structure and opened the door for further downside. Although RSI at 28.00 signals oversold conditions, selling pressure remains dominant. Immediate support is near AUD 2.50; failure to hold this level could trigger deeper declines, with sentiment likely to stay fragile unless the stock reclaims AUD 3.87.

Analyst View

Recovery linked to sustained global travel strength.

FAQs

Why did growth and tech-oriented ASX stocks fall despite the index rising?
Sector rotation into energy and defensive commodity plays led to selling pressure in high-valuation growth segments.

Are BNPL and travel stocks more sensitive to macro conditions?
Yes, both are highly influenced by interest rates, consumer spending trends and global economic visibility.

Is the decline in biotech and SaaS names structural or short term?
Current weakness is largely sentiment and valuation driven, but long-term performance depends on execution, funding and demand cycles.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.